Tevogen Bio Holdings Inc. (TVGN)

Tevogen Bio Holdings, Inc.'s stock (TVGN) has experienced significant fluctuations and underperformed compared to the US Biotechs industry and the broader US Market. As of February 5, 2026, the stock price was $0.28 per share, a -6.00% decrease from the prior week. Over the past year, TVGN underperformed the US Biotechs industry and the US Market. Recent events include the Board evaluating a potential one-time special cash dividend, aligning the long-term stock-based incentive program with company milestones, a drop in TVGN shares, demonstrating platform scalability and multi-indication T cell pipeline expansion, being named to the 2025 New Jersey Power List, Q3 2025 Earnings Release, announcing stronger Q2 and first-half 2025 financial results, and the Annual General Meeting. Analysts anticipate the company to potentially break even in 2027, following a final loss in 2026.

Information regarding the seasonality of demand for Tevogen Bio Holdings, Inc.'s specific products and services is not explicitly detailed. Stock price fluctuations may be influenced by tax loss selling and the "Santa Claus Rally and January effect," but this refers to stock market seasonality rather than the demand for the company's therapeutic products.

Tevogen Bio Holdings, Inc. is a clinical-stage biotechnology company focused on developing personalized cellular immunotherapies. The company develops off-the-shelf, genetically unmodified precision T cell therapies using its ExacTcell™ technology platform for infectious diseases, cancers, and neurological disorders. Key product candidates include TVGN 489, which has completed Phase 1 clinical trials for COVID-19 patients and is in Phase 1 clinical trials for acute SARS-CoV-2 patients with B-cell cancer immune suppression, other B cell immune-suppressed acute SARS-CoV-2 patients with a B cell cancer indication, and for Long COVID prevention and treatment. TVGN 920, TVGN 960, TVGN 601, TVGN 930, and TVGN 116 are in preclinical trials for treating cervical cancer, oropharyngeal cancer, multiple sclerosis, Epstein-Barr virus associated lymphomas, and hepatitis B, respectively. Tevogen also uses its PredicTcell™ AI technology to accelerate target prediction and improve clinical outcomes.

Tevogen Bio Holdings, Inc. is based in the United States, with its corporate office in Warren, New Jersey. The company has expanded its manufacturing facility and headquarters in New Jersey, centralizing R&D, regulatory, and Tevogen.AI operations.

Tevogen Bio Holdings, Inc. has received positive recognition for its contributions to innovation and the economy. Tevogen was named to the 2025 New Jersey Power List by NJBIZ, acknowledging its influential role in shaping New Jersey's economic and innovation landscape. The company was also noted for its projected near-term commercial potential. The Tevogen CEO's donation of shares in December 2025 to support education for underprivileged children also positively impacted its reputation.

Tevogen Bio Holdings Inc. has 99 institutional owners and shareholders, holding a total of 6,059,073 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, IWM - iShares Russell 2000 ETF, FSSNX - Fidelity Small Cap Index Fund, Northern Trust Corp, IBB - iShares Nasdaq Biotechnology ETF, IWO - iShares Russell 2000 Growth ETF, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Portland Global Advisors LLC, Polar Asset Management Partners Inc., Nuveen LLC, HGC Investment Management Inc., and Bridgeway Capital Management LLC. Institutional ownership saw a 60% increase as of March 31, 2025, compared to December 31, 2024, with Vanguard and BlackRock significantly increasing their holdings.